Genome Sequencing Market Report 2026

The genome sequencing market size has grown rapidly in recent years. It will grow from $11.78 billion in 2025 to $14.04 billion in 2026 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to limited availability of advanced sequencing systems, reliance on conventional sanger sequencing, growing genomics research initiatives, increasing government funding for genome projects, rising awareness of personalized medicine.

The genome sequencing market size is expected to see rapid growth in the next few years. It will grow to $28.07 billion in 2030 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to development of next-generation sequencing systems, expansion of bioinformatics platforms, increasing adoption of precision medicine programs, rising collaborations between biotech and pharmaceutical companies, growth in genomic data storage and management solutions. Major trends in the forecast period include increasing adoption of next-generation sequencing (ngs) technologies, rising demand for precision medicine and personalized therapies, expansion of bioinformatics and data analysis services, growth in environmental and microbiome genomics applications, integration of custom genome sequencing solutions in research.

The rising incidence of cancer is expected to drive the growth of the genome sequencing market in the coming years. Cancer comprises a group of diseases characterized by uncontrolled growth and spread of abnormal cells, which can become life-threatening if not treated. The increasing occurrence of cancer is influenced by factors such as aging populations, lifestyle habits, environmental exposures, and genetic susceptibility. Genome sequencing supports cancer management by identifying genetic mutations and inherited predispositions, enabling early detection and the development of personalized treatment plans. It also helps assess inherited cancer risks and monitor the progression of cancerous cells. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, new cancer cases are projected to exceed 35 million by 2050, reflecting a 77% increase from 20 million cases in 2022. Therefore, the growing prevalence of cancer is contributing to the expansion of the genome sequencing market.

Key companies operating in the genome sequencing market are focusing on developing advanced technologies, such as next-generation sequencing (NGS)-based assays, to improve the accuracy of genetic analysis and facilitate personalized medicine. Next-generation sequencing (NGS)-based assays are high-throughput genomic technologies that allow rapid sequencing of DNA or RNA, enabling detailed analysis of genetic material. NGS can sequence millions of DNA or RNA fragments simultaneously, generating large volumes of data efficiently and cost-effectively. For instance, in April 2023, Centogene N.V., a Germany-based provider of genetic diagnostics for rare diseases, launched CentoGenome, an advanced NGS-based assay. CentoGenome offers lifelong diagnostic support through proactive diagnosis confirmation and reclassification programs at no additional cost, ensuring continuous patient care and accurate disease management. Using a PCR-free approach, the platform minimizes bias and enhances sequencing quality, providing improved coverage of challenging genomic regions and better insights into coding, regulatory, and intronic areas. It also integrates an automated bioinformatics pipeline with expert medical analysis, leveraging CENTOGENE’s extensive bio databank of approximately 700,000 patients across more than 120 countries. This comprehensive dataset enhances the detection of disease-causing variants, including those linked to spinal muscular atrophy and Parkinson’s disease.

In January 2023, QIAGEN N.V., a Germany-based provider of sample and assay technologies for research, acquired Verogen Inc. for an undisclosed amount. This acquisition allows QIAGEN to offer a full range of integrated forensic solutions using PCR, digital PCR, and NGS technologies, while also securing exclusive distribution rights. Verogen Inc. is a US-based provider of next-generation sequencing (NGS) solutions for forensic genomics.

Major companies operating in the genome sequencing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Eurofins Genomics, Agilent Technologies Inc., PerkinElmer, Illumina Inc., bioMérieux, Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., BGI Group, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., GENEWIZ Inc., LI-COR Inc., CENTOGENE N.V., Bioneer Corporation, Strand Life Sciences Pvt Ltd., Nebula Genomics.

North America was the largest region in the genome sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genome sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the genome sequencing market by increasing costs for imported sequencing systems, reagents, consumables, and bioinformatics software. Segments such as NGS systems, sequencing chips, and library preparation kits are most affected, particularly in North America, Europe, and Asia-Pacific regions including China and India. This has led to higher operational costs and potential delays in research and diagnostic applications. On the positive side, tariffs have incentivized local manufacturing, domestic R&D investments, and the development of cost-efficient sequencing solutions.

The genome sequencing market research report is one of a series of new reports that provides genome sequencing market statistics, including genome sequencing industry global market size, regional shares, competitors with a genome sequencing market share, detailed genome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the genome sequencing industry. This genome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genome sequencing is the process of determining an organism’s complete DNA sequence. It involves identifying the exact order of nucleotides - adenine, cytosine, guanine, and thymine - across the genome, which encompasses all of an organism’s genetic material. Genome sequencing provides detailed insights into the genetic blueprint of an organism, allowing scientists to study genetic variations, detect mutations, and explore the relationships between genes and traits or diseases.

The main types of genome sequencing products include consumables, systems, software, and services. Consumables are single-use items required for DNA sample preparation, reaction facilitation, and sequencing data capture, ensuring accuracy and efficiency throughout the sequencing process. These products employ technologies such as polymerase chain reaction (PCR), sequencing, microarray, nucleic acid extraction, purification, and others, and are applied across areas including diagnostics, drug discovery, precision medicine, environmental genomics, research, and more. They are utilized by various end users, including hospitals and clinics, biotechnology and pharmaceutical companies, contract research organizations (CROs), government and research centers, academic institutions, and other facilities.

The genome sequencing market consists of revenues earned by entities by providing services such as whole genome sequencing, targeted sequencing, and agri-genomics. The market value includes the value of related goods sold by the service provider or included within the service offering. The genome sequencing market also includes sales of reagents, automated pipettors, and genotyping kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.